Deferasirox
- TRADE NAMES: Exjade (Novartis); Jadenu (Novartis)
- INDICATIONS: Chronic iron overload due to blood transfusions and in non-transfuson dependent thalassemia syndromes
- CLASS: Chelator, iron
- HALF-LIFE: 8–16 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alfuzosin, Aluminum-containing antacids, Ambrisentan, Aprepitant, Cabazitaxel, Cholestyramine, Cilostazol, Colesevelam, Colestipol, Conivaptan, Dabigatran, Darunavir, Dasatinib, Delavirdine, Docetaxel, Efavirenz, Enalapril, Estradiol, Eszopiclone, Fesoterodine, Gefitinib, Indinavir, Ixabepilone, Lapatinib, Lurasidone, Maraviroc, Pazopanib, Phenobarbital, Phenytoin, Pioglitazone, Repaglinide, Rifampin, Ritonavir, Sildenafil, Telithromycin, Theophylline, Tiagabine, Tipranavir, Trimethoprim, Ulipristal
PREGNANCY CATEGORY: C
RENAL FAILURE, HEPATIC FAILURE, AND GASTROINTESTINAL HEMORRHAGE
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
